Differential prognostic value of resistin for cardiac death in patients with coronary artery disease according to the presence of metabolic syndrome

AbstractResistin is associated with atherosclerosis progression by affecting inflammation and insulin resistance. There are controversial data regarding the prognostic value of resistin in stable coronary artery disease (CAD) patients. We prospectively investigated the long-term prognostic value of resistin in patients with stable CAD. A total 741 consecutive patients with stable CAD were followed for a median of 5.5  years. Serum resistin, lipids, high-sensitivity C-reactive protein (hsCRP) and interleukin-6 (IL-6) levels were measured at baseline. Primary endpoints were cardiac death and secondary hospitalizations for acute coronary syndrome, arrhythmic event or ischemic stroke. Follow-up data were obtained f rom 703 patients of whom 79 had a cardiac death (11.2%) and 205 (29.2%) met the secondary endpoints. Resistin was positively correlated with hsCRP (r = 0.159,p <  0.001) and IL-6 (r = 0.165,p = 0.002), and negatively with high-density lipoprotein-cholesterol (r = − 0.176,p <  0.001). Resistin levels could not predict cardiac death [HR 1.044; 95% CI 0.994–1.096;p = 0.087] neither secondary endpoints [HR 1.025; 95% CI 0.983–1.068;p = 0.250). Among 298 patients (42.4%) with metabolic syndrome (MS) resistin levels were independently associated with cardiac death after adjustment for conventional risk factors [HR 1.121; 95% CI 1.045–1.204;p = 0.002). Further adjustment for ejection fraction of left ventricle (LVEF) did no...
Source: Heart and Vessels - Category: Cardiology Source Type: research